Categories AlphaGraphs, Earnings, LATEST, Other Industries

Biogen posts solid Q3 results, topping expectations

Biogen Inc. (BIIB) beat market expectations on revenue and earnings for the third quarter of 2018. Total revenues grew 12% to $3.4 billion from the prior-year period, helped by strength in SPINRAZA and biosimilars, as well as OCREVUS royalties.

On a GAAP basis, net income grew 18% to $1.44 billion and EPS grew 24% to $7.15 year-over-year. Adjusted net income grew 12% to $1.49 billion and adjusted EPS grew 17% to $7.40. Earnings in the quarter benefited from a lower tax rate and a lower share count.

Biogen third quarter 2018 Earnings Infographic
Biogen Q3 2018 Earnings Infographic

Total product revenues grew 6% to $2.78 billion. The company’s core multiple sclerosis (MS) business remained stable during the quarter while SPINRAZA benefited from higher patient demand both within and outside the US. Biogen is trying to expand its pipeline beyond its MS and Alzheimer’s portfolios and made progress in stroke, progressive supranuclear palsy and ALS during the third quarter.

In multiple sclerosis, TECFIDERA revenues improved 2% year-over-year. In spinal muscular atrophy, SPINRAZA revenues rose 73% while in biosimilars, revenues grew 33%. Revenues declined for all the other products on a year-over-year basis. During the quarter, channel inventory levels in the US remained stable for TECFIDERA, AVONEX and PLEGRIDY combined.

Biogen recorded SPINRAZA revenues in over 30 countries during the third quarter. On a sequential basis, the number of commercial patients receiving SPINRAZA grew around 11% in the US and around 29% internationally.

Biogen stock gains on upbeat Q2 results

In the third quarter, the company’s board authorized a program to repurchase up to $3.5 billion of its common stock. As of September 30, Biogen had cash, cash equivalents and marketable securities totaling approx. $5.7 billion and around $5.9 billion in notes payable.

Biogen’s shares were up 2.5% in early trading hours on Tuesday. The stock is up 2% thus far this year.


Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

One thought on “Biogen posts solid Q3 results, topping expectations

Comments are closed.


Add Comment
Viewing Highlight